Sanofi

18 Mars 2005 17:00

FDA Advisory Panel Recommends Licensure of sanofi pasteurs ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis

Vaccine Leader Looks to Introduce First Pertussis Booster for Both Adolescents and Adults in United States Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) voted unanimously to recommend licensure of ADACEL (Tetanus Toxoi

17 Mars 2005 10:01

Sanofi Pasteur seeks to broaden age group for new vaccine, Menactra, to protect against meningococcal disease

Submits supplemental license application Sanofi Pasteur, the vaccines business of the sanofi-aventis Group, is seeking U.S. government approval to broaden the age indication for its new meningococcal vaccine Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine). The company has filed a supplemental application with the U.S. Food and Drug Adminis

14 Mars 2005 09:14

Sanofi-aventis sues Novopharm for patent infringement in Canada

Sanofi-aventis has learned through the Canadian Ministry of Health website that Novopharm Limited had obtained marketing approval in Canada for a product claiming to be generic enoxaparin. Sanofi-aventis companies Aventis Pharma Inc. and Aventis Pharma S.A. are bringing suit in the Federal Court against Novopharm for patent infringement of Canadian patent 2045433, which covers Lovenox®. Sanofi

9 Mars 2005 16:04

Clopidogrel improved coronary perfusion and reduced mortality in acute heart attack

Results from two major clinical trials presented at ACC (PARIS and PRINCETON, NJ, MARCH 9, 2005) Results of two major clinical trials showed that the antiplatelet agent clopidogrel, given on top of standard therapy, provided significant benefits to patients with acute ST-segment elevation myocardial infarction (STEMI), a certain kind of heart attack. Results of the COMMIT/CCS-2 (ClOpidogrel

2 Mars 2005 15:49

Sanofi Aventis och Pfizer seek approval to market Exubera® in the United States

Pfizer Inc. and the sanofi-aventis Group announced today that the United States Food and Drug Administration (FDA) has accepted for filing a new drug application for Exubera® (inhaled human insulin powder). Exubera®, a dry powder form of insulin that is inhaled into the lungs prior to eating, using a specially designed inhalation device, has been studied in more than 3,500 patients, some for o

28 Februari 2005 13:58

Personalförändring i sanofi-aventis

Tommy Olin, commercial operations director, med ansvar för sanofi-aventis sälj- och marknadsorganisation har valt att lämna företaget för att gå vidare i en ny karriär utanför organisationen. Han lämnar sanofi-aventis vid månadsskiftet. För ytterligare information kontakta Annette Hedman, tf informationsanvarig, 08-470 18 52 eller 070-289 88 64. Koncernen sanofi-aventis är det tredje störst

3 Februari 2005 09:40

Sanofi-aventis receives FDA approval for new Eloxatin® formulation

Sanofi-aventis announced today that he has received marketing approval from the United States Food and Drug Administration for a new formulation of Eloxatin® (oxaliplatin for injection). This new formulation, Eloxatin® INJECTION, is a clear, preservative-free, colorless solution which does not require reconstitution. Eloxatin® INJECTION offers additional benefit and convenience to physicians an

31 Januari 2005 09:41

Studies demonstrate significant benefit of Eloxatin

TWO STUDIES DEMONSTRATE SIGNIFICANT BENEFIT OF ELOXATIN BASED CHEMOTHERAPY COMBINED WITH BEVACIZUMAB IN ADVANCED COLORECTAL CANCER Positive Results of TREE-2 and ECOG 3200 Trials Presented at the 2005 Gastrointestinal Cancers Symposium in Hollywood, Florida Sanofi-aventis (NYSE: SNY) announced today preliminary results of two large prospective trials evaluating the safety and efficacy of E

26 Januari 2005 11:57

2004 pro forma combined net sales up 10.0% on a comparable basis

Sanofi-aventis gains market share from year one After consultation with the stock market authorities in France and the United States, sanofi-aventis has retained August 20 as the date of first consolidation. In 2004, sanofi-aventis generated consolidated net sales of 15,043 million euros compared with 8,048 million euros in 2003. In the fourth quarter of 2004, sanofi-aventis consolidated net

25 Januari 2005 15:04

Nytt hopp för kvinnor med tidig bröstcancer

EU-kommissionen har godkänt sanofi-aventis läkemedel Taxotere (docetaxel) för adjuvant behandling, det vill säga direkt efter operation, vid tidig körtelpositiv bröstcancer. Kommissionens beslut baseras på resultatet av en stor långtidsstudie som visar på både en ökad överlevnad och minskad risk för återfall vid behandling med Taxotere. - Detta är framsteg vad gäller bröstcancerbehandling. Resu

25 Januari 2005 11:52

Sanofi-aventis solidarity day in favour of South East Asia Sharing in solidarity

Sanofi-aventis organizes today, January 25, 2005, a solidarity day in 300 sanofi-aventis sites worldwide to allow Group collaborators to take part in actions undertaken with partner aid agencies in the tsunami-stricken countries. Each employee will be able to share in the movement of solidarity by opting, either to make financial donation to the projects of the villages twinned with his or her

25 Januari 2005 11:50

Plavix® patent

Sanofi-aventis has been notified that its patent in the UK issued from its European Patent claiming the active ingredient in its Plavix® product has been challenged by Aircoat, Ltd., a Scottish company, in a Scottish Court. Sanofi-aventis believes Aircoat's arguments to be without merit, and will vigorously defend its patent. Forward-looking statements: This press release contains forward-look

Nyhetsarkiv

FDA Advisory Panel Recommends Licensure of sanofi pasteurs ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis

Sanofi Pasteur seeks to broaden age group for new vaccine, Menactra, to protect against meningococcal disease